Gram-positive toxic shock syndromes

被引:270
作者
Lappin, Emma [2 ]
Ferguson, Andrew J. [1 ]
机构
[1] Dalhousie Univ, Dept Med, Div Crit Care, Halifax, NS B3H 2Y9, Canada
[2] Craigavon Area Hosp, Dept Anaesthesia & Intens Care Med, Portadown, North Ireland
关键词
A STREPTOCOCCAL INFECTIONS; NF-KAPPA-B; INTRAVENOUS IMMUNOGLOBULIN THERAPY; STAPHYLOCOCCAL-ENTEROTOXIN-B; SCARLET FEVER TOXIN; TOLL-LIKE RECEPTORS; HLA CLASS-II; UNITED-STATES; BACTERIAL SUPERANTIGEN; SEXUAL-DIMORPHISM;
D O I
10.1016/S1473-3099(09)70066-0
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Toxic shock syndrome (TSS) is an acute, multi-system, toxin-mediated illness, often resulting in multi-organ failure. It represents the most fulminant expression of a spectrum of diseases caused by toxin-producing strains of Staphylococcus aureus and Streptococcus pyogenes (group A streptococcus). The importance of Gram-positive organisms as pathogens is increasing, and TSS is likely to be underdiagnosed in patients with staphylococcal or group A streptococcal infection who present with shock. TSS results from the ability of bacterial toxins to act as superantigens, stimulating immune-cell expansion and rampant cytokine expression in a manner that bypasses normal MHC-restricted antigen processing. A repetitive cycle of cell stimulation and cytokine release results in a cytokine avalanche that causes tissue damage, disseminated intravascular coagulation, and organ dysfunction. Specific therapy focuses on early identification of the illness, source control, and administration on antimicrobial agents including drugs capable of suppressing toxin production (eg, clindamycin, linezolid). Intravenous immunoglobulin has the potential to neutralise superantigen and to mitigate subsequent tissue damage.
引用
收藏
页码:281 / 290
页数:10
相关论文
共 94 条
[1]   Toll-like receptor signaling [J].
Akira, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (40) :38105-38108
[2]   Staphylococcal and streptococcal superantigens:: molecular, biological and clinical aspects [J].
Alouf, JE ;
Müller-Alouf, H .
INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY, 2003, 292 (7-8) :429-440
[3]   Managing toxic shock syndrome with antibiotics [J].
Annane, D ;
Clair, B ;
Salomon, J .
EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (08) :1701-1710
[4]   Progress toward characterization of the group a Streptococcus metagenome:: Complete genome sequence of a macrolide-resistant serotype M6 strain [J].
Banks, DJ ;
Porcella, SF ;
Barbian, KD ;
Beres, SB ;
Philips, LE ;
Voyich, JM ;
DeLeo, FR ;
Martin, JM ;
Somerville, GA ;
Musser, JM .
JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (04) :727-738
[5]   The fundamental contribution of phages to GAS evolution, genome diversification and strain emergence [J].
Banks, DJ ;
Beres, SB ;
Musser, JM .
TRENDS IN MICROBIOLOGY, 2002, 10 (11) :515-521
[6]   INTRAVENOUS IMMUNOGLOBULIN THERAPY FOR TOXIC SHOCK SYNDROME [J].
BARRY, W ;
HUDGINS, L ;
DONTA, ST ;
PESANTI, EL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (24) :3315-3316
[7]  
Basma H, 1999, INFECT IMMUN, V67, P1871
[8]   STAPHYLOCOCCAL AND STREPTOCOCCAL PYROGENIC TOXINS INVOLVED IN TOXIC SHOCK SYNDROME AND RELATED ILLNESSES [J].
BOHACH, GA ;
FAST, DJ ;
NELSON, RD ;
SCHLIEVERT, PM .
CRITICAL REVIEWS IN MICROBIOLOGY, 1990, 17 (04) :251-272
[9]   Beyond MRSA: The growing menace of hVISA and VISA [J].
Bulchandani, Deepti ;
Nachnani, Jagdish ;
Fitzsimmons, Curtis ;
Jost, Paul ;
Brewer, Joseph .
SOUTHERN MEDICAL JOURNAL, 2008, 101 (06) :663-664
[10]   Overview of the human immune response [J].
Chaplin, DD .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (02) :S430-S435